Industry Overview - Dental implant industry involves surgical placement of artificial materials into the jawbone to serve as artificial tooth roots, followed by the installation of crowns [1] - The process includes four main steps: implant placement, waiting for osseointegration, installing abutments, and placing crowns [1] Industry Chain Analysis - The upstream of the dental implant industry includes raw material suppliers, equipment manufacturers, and software developers, with titanium and zirconia being key materials [4][5] - Midstream consists of implant manufacturers and distributors, while downstream includes dental institutions providing implant services to patients [4][5] Industry Development History - The industry has evolved through three main phases: 1. Emergence phase (1980-2000) with initial education and product development [7] 2. Dominance of foreign brands (2000-2010) with a focus on public institutions [10] 3. Rise of domestic brands (2020-present) with a shift towards high-quality local products [10] Industry Policy Direction - Policies focus on reducing medical costs, standardizing management, improving service quality, promoting talent development, and supporting digital technology applications [12] - Key policies include price standardization for dental services and promoting centralized procurement to enhance transparency and reduce costs [12][14] Current Industry Status - Dental implants account for 40% of the total implant costs, with a significant portion of the market still dominated by international brands [15][16] - The number of dental implants in China is projected to exceed 10 million by 2024, driven by increased demand and lower prices due to centralized procurement [18] Market Size and Growth - The dental implant market in China is expected to surpass 60 billion yuan by 2024, with significant price reductions leading to increased accessibility [21] - The average cost of a single implant has dropped to 5,000-7,000 yuan due to policy changes, representing a 50% decrease [21] Competitive Landscape - The market is characterized by a high concentration, with leading companies like Dentium and Osstem dominating the first tier, while others like Straumann and Nobel Biocare are in the second tier [23][26] - The market concentration ratio (CR2) is 45.78%, indicating a competitive environment with a mix of domestic and international brands [26] Future Development Trends - The demand for dental implants is expected to grow due to an aging population and increased awareness of oral health [28] - The implementation of centralized procurement policies will further stimulate market demand and enhance the penetration of domestic brands [28] - Innovations in technology, such as 3D printing and robotic-assisted surgeries, will improve the precision and efficiency of dental implants [28] - By 2030, the market size is projected to reach 277 billion yuan, with an average annual growth rate of 29% [28]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongce Medical, which closed at 40.74 yuan with a PE ratio of 35.58 times, and a total market capitalization of 18.223 billion yuan [1][2] - The average PE ratio for the medical services industry is 39.95 times, with a median of 41.77 times, positioning Tongce Medical at the 26th rank within the industry [1][2] - As of the first quarter of 2025, 21 institutions hold shares in Tongce Medical, including 18 funds, with a total holding of 209.5898 million shares valued at 9.488 billion yuan [1] Group 2 - Tongce Medical's main business focuses on providing oral medical services and research, with key products including medical services, product sales, construction engineering, and comprehensive service fees [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 745 million yuan, representing a year-on-year increase of 5.11%, and a net profit of 184 million yuan, up by 6.22%, with a gross profit margin of 44.21% [1]

通策医疗股份有限公司 证券代码：600763 证券简称：通策医疗 编号：临 2025-015 关于 2024 年度暨 2025 年第一季度业绩暨 现金分红说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）2024年度暨2025年第一季度业 绩暨现金分红说明会(以下简称"说明会")于2025年6月24日（星期二）15：00-16： 30于上海证券交易所上证路演中心以视频直播和网络互动方式召开。公司董事长 兼总经理王毅女士、独立董事王绪强先生、董事会秘书张华先生、财务总监徐国 喜先生等出席本次说明会，与投资者进行沟通和交流，投资者交流的主要问题及 回复概要如下： 1.2024年度及2025年Q1公司的业绩情况说明。 2024 年，面对消费需求分层、种植牙集采全面落地，行业格局加速重构， 公司稳扎稳打、稳中求进，以"医疗质量立本、客户价值为先、数据驱动创新" 为战略核心，聚焦降本增效、数字化升级与资源整合三大主线，在逆势中实现了 高质量发展。报告期内，公司实现营业收入 ...

证券简称：通策医疗 证券代码：600763 编号：临 2025-014 通策医疗股份有限公司 关于参股基金进入清算期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"、"通策医疗"）于今日收到参股基 金浙江通策壹号投资合伙企业（有限合伙）（以下简称"壹号基金"、"参股基金"） 进入清算期的通知。 一、壹号基金基本情况 医疗股份有限公司关于以妇幼子公司股权参与基金投资暨关联交易的公告》 浙江通策壹号投资合伙企业（有限合伙）系旨在从事妇幼产业专项投资业务，为 全体合伙人创造良好投资回报，实现资本增值的私募股权投资基金。 | 基金名称 | 浙江通策壹号投资合伙企业(有限合伙) | | --- | --- | | 统一社会信用代码证 | 91330624MA29DW6PX5 | | 基金编码 | SW6104 | | 基金类型 | 股权投资基金 | | 基金注册地 | 浙江省绍兴市新昌县南明街道大佛寺 8 号 1 幢 | | 基金成立日期 | 2017/9/13 | | 基金备案日期 ...

Group 1 - The core viewpoint of the article highlights the competitive landscape of the Chinese dental implant industry, focusing on market concentration and the positioning of key players [1][4][10] - The first tier of the competitive hierarchy includes Dentsply Sirona and Osstem Implant, with procurement amounts exceeding 15 million yuan, significantly surpassing other companies [1][4] - The market share of foreign brands, particularly mid-range Korean brands, is substantial, while domestic brands have a lower overall market share [4][10] Group 2 - The market concentration in the dental implant sector is high, with a CR2 of 45.78% and a CR5 of 69.94%, indicating a strong presence of leading mid-range Korean and high-end European brands [5][10] - The competitive environment is characterized by numerous players, including public dental hospitals and large chain dental institutions, which have advantages in brand recognition and technology [10][11] - The entry barriers in the dental implant industry are significant due to the need for specialized talent, advanced equipment, and time-consuming brand building [11][12] Group 3 - The regional layout of key listed companies shows that most operate primarily within China, with specific companies focusing on particular provinces, such as Keren Dental in Shandong and Blue Sky Dental in Guangxi [6][9] - Revenue from dental implant services is notably high for companies like Tongce Medical, Yaboshi, and Reer Group, indicating strong market performance [6][9] - The article emphasizes the increasing preference for dental implants over traditional dentures, as patients seek better functionality and aesthetics [11][12]

通策医疗股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600763 证券简称：通策医疗 公告编号：2025-013 会议召开时间：2025 年 06 月 24 日（星期二）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 06 月 17 日（星期二）至 06 月 23 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lianghao@eetop.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 https://roadshow.sseinfo.com/） 二、说明会召开的时间、地点 通策医疗股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发布公 司 2024 年度报告、2025 年一季度报告，为便于广大投资者更全面深入地了解公 司 20 ...

截至2025年6月13日收盘，通策医疗（600763）报收于41.47元，较上周的41.95元下跌1.14%。本周，通 策医疗6月9日盘中最高价报43.48元。6月13日盘中最低价报41.21元。通策医疗当前最新总市值185.49亿 元，在医疗服务板块市值排名8/50，在两市A股市值排名832/5150。 公司公告汇总 通策医疗股份有限公司发布2024年年度权益分派实施公告，主要内容如下：- A股每股现金红利0.45 元。- 股权登记日为2025年6月17日，除权（息）日及现金红利发放日均为2025年6月18日。- 分红方案 以公司总股本447289117股为基数，每股派发现金红利0.45元（含税），共计派发现金红利201280102.65 元。- 无限售条件流通股的红利委托中国结算上海分公司派发；杭州宝群实业集团有限公司、吕建明为 自行发放对象。- 对于持有无限售条件流通股的个人股东及证券投资基金，根据持股期限不同，适用不 同的个人所得税政策；对于合格境外机构投资者（QFII）股东，按10%的税率代扣代缴企业所得税；对 于香港市场投资者通过沪港通投资本公司A股股票的，公司按照10%的税率代扣代缴所得税；对于 ...

Core Viewpoint - The company has announced a cash dividend of 0.45 CNY per share, totaling approximately 201.28 million CNY, to be distributed to shareholders [2][3][5]. Dividend Distribution Details - The cash dividend distribution was approved at the annual general meeting held on June 5, 2025 [2]. - The total number of shares for the dividend calculation is 447,289,117 shares [2]. - The key dates for the dividend distribution are as follows: - Record date: June 17, 2025 - Last trading date: June 18, 2025 - Ex-dividend date: June 18, 2025 [2]. Taxation Information - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax [3]. - For shares held for one month or less, 50% of the dividend is included in taxable income, subject to a 20% tax rate [3][5]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax applies, resulting in a net dividend of 0.405 CNY per share after tax [6]. - For Hong Kong investors, the same 10% withholding tax applies, leading to a net dividend of 0.405 CNY per share [6]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Securities Affairs Department at 0571-88868808 [5].

证券代码：600763 证券简称：通策医疗 公告编号：2025-012 通策医疗股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.45元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/17 | － | 2025/6/18 | 2025/6/18 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 5 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本447,289,117股为基数，每股派发 ...

截至2025年6月6日收盘，通策医疗(600763)报收于41.95元，下跌0.43%，换手率0.84%，成交量3.77万 手，成交额1.59亿元。 会议审议通过了七项非累积投票议案，包括：1. 2024年年度报告2. 董事会工作报告3. 监事会工作报告4. 2024年度利润分配方案5. 2024年度财务决算报告6. 续聘会计师事务所议案7. 修订公司章程议案 各议案均获得高比例支持，具体表决情况见公告。现金分红分段表决结果显示，持股5%以上和1%-5% 的普通股股东全部同意，持股1%以下普通股股东中89.2999%同意。涉及重大事项时，5%以下股东对利 润分配方案、续聘会计师事务所和修订公司章程议案的支持率分别为97.3250%、97.3024%和 97.1902%。 浙江天册律师事务所朱纯怡律师和李沛雨律师见证了本次股东大会，并认为会议合法有效。 浙江天册律师事务所为通策医疗股份有限公司2024年年度股东大会出具法律意见书，认为本次股东大会 的召集与召开程序、出席会议人员的资格、会议表决程序均符合法律法规和公司章程规定，表决结果合 法有效。 当日关注点 交易信息汇总 6月6日，通策医疗的资金流向显示，主力 ...